Pretty interesting story in @ScienceMagazine this week on what looks like a serious problem in the senescence field. More than 400 papers apparently used the wrong antibody for p16-INK4a — an antibody that actually recognizes a completely different, unrelated protein (a component of the actin cytoskeleton). This affects work on senescent cell accumulation in aging and disease, and most critically, some of the evidence base for senolytic drug research. What concerns me most is that many of these papers somehow got the "right" answer using the wrong antibody. That's not just an innocent reagent mix-up — it raises real questions about data fabrication or selective reporting in at least some of these labs. I've commented before about how ignoring data that doesn't fit the narrative is a major problem in certain areas of the longevity literature (e.g. sirtuins and NAD), and here a potentially widespread example in senescence. Hopefully journals will investigate and retract as necessary, but based on my experience that seems optimistic. One concrete fix is that journals should flag problematic antibody product codes at submission so reviewers can catch this before publication. Reviewers should absolutely be on the lookout for this going forward. However, these fixes won't address the larger problem. We need to understand how these scientists got the results they wanted and published them over 400 times (!!!): whether through intentional deception, incompetence, accident, or some legitimate explanation. Credit for discovering this goes to @addictedtoigno1 who wrote about it first on his blog: For Better Science science.org/content/article/…?

In case you still think there is any normalcy in how scientists are being treated at NIH. Photo credit: 27UNIHTED

Asked mid-season about the Yankees, former Red Sox General Manager Theo Epstein once said that he had looked at their roster at the start of the season, realized that they'd win 100 games, and now ignored their weekly standings in order to focus on his own roster's ability to compete. I raised this anecdote at a recent roundtable of experts discussing China's rise in biotechnology. China is uplifting scientists, investing hundreds of billions in R&D, and accelerating clinical trials. It's going to win 100 games. The center of biomedical gravity is moving to China from America, just like it moved from Europe to America at the close of last century. Unless America decides to win 110 games. statnews.com/2026/05/18/biot…

Excited for ⁦@cwrumstp⁩ and new Abbott lab alum, Michelle Pan, to defend her dissertation today! Congratulations to Dr Pan. Look out for her paper coming out in a couple of weeks!

This weekend, my wife and I were very excited to attend our first Beaux Arts Ball at National Jewish Health. Its very inspiring to work at an institution dedicated to finding treatments and cures for immunologic diseases and to work with such a dedicated team. @KathrynTeng

Pleased to share a new review article focusing on Gasdermin D's role in Pathology spearheaded by Bowen Zhou, a former @cwrumstp student and current Pathology fellow @UHhospitals annualreviews.org/content/jo…

Is the consensus on the new online NIH Biosketch that we cannot list manuscripts in the "Contributions to Science" section? @drugmonkeyblog

Shiga toxin-induced cell death—the underlying cause of a potentially fatal renal disease in children—occurs via pyroptosis, not apoptosis as previously thought, and is driven by an intriguing NLRP1->Caspase-3-> gasdermin E pathway. Congrats to Priya's lab! pnas.org/doi/10.1073/pnas.25…

This isn’t the case at National Jewish Health. We are actively hiring to expand our tenure track faculty in Immunology and genomic medicine. linkedin.com/pulse/pulling-u…

FDA approves 100th small-molecule kinase inhibitor nature.com/articles/d41573-0… From the landmark approval of the anticancer drug imatinib almost a quarter century ago, our latest news feature analyses trends in the field of kinase inhibitors, now one of the major drug classes

Came into lab today to do cell culture work and found a lady bug in my hood!!

At the Alexandra Kay show in the CLE with ⁦@KathrynTeng⁩ !!!!

Might we suggest "Proving Grounds" with @UVAMensHoops , @trillydonovan ? virginiasports.com/news/2025…

Application now open: Career Awards for Medical Scientists (CAMS) is a highly competitive program that provides $700,000 awards over 5 years for physician-scientists, who are committed to an academic career Deadline: 10/07/25 buff.ly/VdljzxQ #bwfcams

New review from our lab. Kudos to PhD student @SebGrant346534. 10 things you wish you knew about inflammatory caspases: a holistic review of their biochemistry, activation, and signalling - Journal of Biological Chemistry jbc.org/article/S0021-9258%2…

Application now open: Career Awards for Medical Scientists (CAMS) is a highly competitive program that provides $700,000 awards over 5 years for physician-scientists, who are committed to an academic career Deadline: 10/07/25 buff.ly/VdljzxQ #bwfcams